Brian Mehling, MD has successfully completed all components of the Board Certification in the field of Anti-Aging and Regenerative Medicine.
Dr. Mehling is the founder and chief medical officer of Mehling Orthopedics and BHI Therapeutic Sciences (BHITS). He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He spearheads groundbreaking research in stem cell therapy. Notably, BHITS is currently engaged in an FDA Investigational New Drug trial for stroke, using human umbilical cord blood (hUCB) stem cells.
“Cellular medicine is in high demand and stem cells have the potential to treat a wide range of diseases. Stem cells are essentially “blank slate” cells that possess the remarkable potential to differentiate to any one of the billions of cells that form the diverse tissues of the human body. In addition, stem cells have the power to divide virtually without limits and convert or develop into specialized cells that can replace injured or damaged tissue.”
Completing his degree of medicine at Wright State University School of Medicine, Dr. Mehling received post graduate education through residencies and fellowships at St. Joseph’s Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a Ph.D. in Chemistry (which he is currently completing at Seton Hall University).
Founded in 1992 by Dr. Ronald Klatz and Dr. Robert Goldman, The American Academy of Anti-Aging Medicine (A4M) is rooted in a forward-focused mission to redefine modern medicine, The American Academy of Anti-Aging Medicine (A4M) is the established global leader for continuing medical education in longevity medicine, metabolic resilience, and whole-person care.
